Ovaprene® (DARE-LARC1)
Hormone-Free Contraception
Phase 3Active (Positive Interim Results)
Key Facts
Indication
Hormone-Free Contraception
Phase
Phase 3
Status
Active (Positive Interim Results)
Company
About Dare Bioscience
Daré Bioscience is a mission-driven, clinical-stage biotech pioneering evidence-based therapeutics exclusively for women's health. The company has achieved a key milestone with the commercial launch of DARE to PLAY™ Sildenafil Cream, the first FDA-approved topical treatment for female sexual arousal disorder, while advancing a broad pipeline including hormone-free contraception and a novel HPV treatment. Its strategy centers on leveraging localized drug delivery platforms to improve safety and efficacy, targeting large, underserved markets with high unmet need. Operating as a lean, virtual R&D organization, Daré partners with CROs and leverages non-dilutive funding to advance its programs toward commercialization.
View full company profileTherapeutic Areas
Other Hormone-Free Contraception Drugs
| Drug | Company | Phase |
|---|---|---|
| Ovaprene® | Daré Bioscience | Phase 3 |